ScholarGate
Asistent

Porovnat metody

Prohlédněte si vybrané metody vedle sebe; řádky, které se liší, jsou zvýrazněny.

Rizikově přizpůsobená klinická studie fáze I×Bayesovský klinický hodnocení fáze I×
OborEpidemiologieEpidemiologie
RodinaProcess / pipelineProcess / pipeline
Rok vzniku1990s–2000s1990
TvůrceEvolved from the Continual Reassessment Method (O'Quigley et al., 1990) extended with patient-level risk covariatesO'Quigley, Pepe & Fisher (Continual Reassessment Method)
TypInterventional clinical trial designAdaptive Bayesian dose-finding design
Původní zdrojIasonos, A., Wilton, A. S., & Gonen, M. (2008). A review of stochastic dose-finding methods. Statistics in Medicine, 27(25), 5031–5046. link ↗O'Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46(1), 33–48. DOI ↗
Další názvyrisk-stratified Phase I trial, risk-adaptive dose-escalation study, covariate-adjusted Phase I study, risk-based dose-finding trialBayesian dose-finding trial, CRM trial, continual reassessment method trial, Bayesian dose-escalation study
Příbuzné55
ShrnutíA risk-adjusted Phase I clinical trial is a first-in-human or dose-finding study that explicitly incorporates patient-level risk covariates — such as organ function, prior therapy, or genetic markers — into the dose-escalation model. Rather than treating all enrolled participants as homogeneous, the design accounts for individual differences in tolerance, allowing the recommended dose to vary by risk stratum. This approach is especially common in oncology, where patients with impaired renal function or heavily pre-treated disease may tolerate lower doses than the broader population.A Bayesian Phase I clinical trial uses prior probability models and sequential Bayes updating to find the maximum tolerated dose (MTD) of a new agent. Unlike the traditional 3+3 rule-based escalation, the Bayesian approach revises a dose-toxicity curve continuously as each patient's outcome is observed, allowing faster convergence to the true MTD while minimising exposure of patients to unsafe or subtherapeutic doses.
ScholarGateDatová sada
  1. v1
  2. 2 Zdroje
  3. PUBLISHED
  1. v1
  2. 2 Zdroje
  3. PUBLISHED

Přejít na hledání Stáhnout prezentaci

ScholarGatePorovnat metody: Risk-adjusted Phase I clinical trial · Bayesian Phase I clinical trial. Získáno 2026-06-20 z https://scholargate.app/cs/compare